A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

Current health news highlights include Pope Francis returning to ventilation for respiratory issues, Sun Pharma's anti-obesity drug launch plans, and Gilead Sciences' $200 million HIV drug probe ...

HumanX, the world's most important AI conference, has announced its return for 2026, with a new location and expanded programming to reflect the industry's rapid evolution. The event's second edition ...

Sartaba/Alexandrium was built by the Hasmoneans and expanded by Herod. A team of archaeologists has launched a first ...

Global design and BIM software provider Vectorworks, Inc. is pleased to announce the return of its Open House event, taking place on March 24 from 7 to 10 p.m. ET and March 25 from 10 a.m. to 1 p.m.

A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The location is the company's headquarters for ... let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM Biosciences: After ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

FOSTER CITY, Calif., February 19, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences ...